BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30303127)

  • 1. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
    Lecouvet FE; Oprea-Lager DE; Liu Y; Ost P; Bidaut L; Collette L; Deroose CM; Goffin K; Herrmann K; Hoekstra OS; Kramer G; Lievens Y; Lopci E; Pasquier D; Petersen LJ; Talbot JN; Zacho H; Tombal B; deSouza NM
    Lancet Oncol; 2018 Oct; 19(10):e534-e545. PubMed ID: 30303127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
    Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
    Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
    Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
    World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.
    Pasoglou V; Michoux N; Van Damme J; Van Nieuwenhove S; Halut M; Triqueneaux P; Tombal B; Lecouvet FE
    World J Urol; 2019 Dec; 37(12):2585-2595. PubMed ID: 30826887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
    Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
    Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligometastatic prostate cancer: The game is afoot.
    Lancia A; Zilli T; Achard V; Dirix P; Everaerts W; Gomez-Iturriaga A; Ingrosso G; Liefhooghe N; Miralbell R; Siva S; Van der Eecken K; Ost P
    Cancer Treat Rev; 2019 Feb; 73():84-90. PubMed ID: 30684842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
    Pasquier D; Bidaut L; Oprea-Lager DE; deSouza NM; Krug D; Collette L; Kunz W; Belkacemi Y; Bau MG; Caramella C; De Geus-Oei LF; De Caluwé A; Deroose C; Gheysens O; Herrmann K; Kindts I; Kontos M; Kümmel S; Linderholm B; Lopci E; Meattini I; Smeets A; Kaidar-Person O; Poortmans P; Tsoutsou P; Hajjaji N; Russell N; Senkus E; Talbot JN; Umutlu L; Vandecaveye V; Verhoeff JJC; van Oordt WMH; Zacho HD; Cardoso F; Fournier L; Van Duijnhoven F; Lecouvet FE
    Lancet Oncol; 2023 Aug; 24(8):e331-e343. PubMed ID: 37541279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
    Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
    World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
    Guckenberger M; Lievens Y; Bouma AB; Collette L; Dekker A; deSouza NM; Dingemans AC; Fournier B; Hurkmans C; Lecouvet FE; Meattini I; Méndez Romero A; Ricardi U; Russell NS; Schanne DH; Scorsetti M; Tombal B; Verellen D; Verfaillie C; Ost P
    Lancet Oncol; 2020 Jan; 21(1):e18-e28. PubMed ID: 31908301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
    deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
    Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
    Decaestecker K; De Meerleer G; Ameye F; Fonteyne V; Lambert B; Joniau S; Delrue L; Billiet I; Duthoy W; Junius S; Huysse W; Lumen N; Ost P
    BMC Cancer; 2014 Sep; 14():671. PubMed ID: 25223986
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
    World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
    Kim J; Park JS; Ham WS
    Investig Clin Urol; 2017 Sep; 58(5):307-316. PubMed ID: 28868501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
    Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A
    Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.
    Deek MP; Taparra K; Dao D; Chan L; Phillips R; Gao RW; Kwon ED; Deville C; Song DY; Greco S; Carducci MA; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Stish BJ; Tran PT
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):387-395. PubMed ID: 32798608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
    Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.